Nilotinib appears safe and affects biomarkers in Alzheimer’s disease clinical trial

WASHINGTON – A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer’s disease finds that it is safe and well-tolerated, and researchers say the drug should be tested in a larger study to further determine its safety and efficacy as a potential disease-modifying strategy. The results of the small,…

Details

Genestack signs multi-year agreement with AstraZeneca to implement Omics Data Manager

Cambridge, UK, May 2020 – Genestack Ltd. today announced that its flagship multi-omics data catalogue, curation and integrative search product, Omics Data Manager (ODM), has been licensed and implemented by AstraZeneca. Genestack’s ODM is an enabling technology providing a central hub for organising and querying multi-omics data from multiple sites, including transcriptomics and proteomics. Curation…

Details

Dietary and physical activity intervention reduces LDL cholesterol level in children

An individualised and family-based physical activity and dietary intervention reduced the plasma LDL cholesterol concentration of primary school children, a new study from the University of Eastern Finland shows. The findings of the Physical Activity and Nutrition in Children (PANIC) Study ongoing at the University of Eastern Finland were published in the European Journal of…

Details

Next frontier in bacterial engineering

From bacteria-made insulin that obviates the use of animal pancreases to a better understanding of infectious diseases and improved treatments, genetic engineering of bacteria has redefined modern medicine. Yet, serious limitations remain that hamper| progress in numerous other areas. A decades-old bacterial engineering technique called recombineering (recombination-mediated genetic engineering) allows scientists to scarlessly swap pieces…

Details

Immunotherapy for bowel cancer could change clinical practice

A large international trial involving UCL and University College London Hospitals NHS Foundation Trust (UCLH) has found that pembrolizumab, a form of immunotherapy, more than doubled the ‘progression free survival’ time of patients with a specific subtype of advanced bowel cancer, when compared with chemotherapy. ‘Progression free survival’ is the length of time during and…

Details